Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lithium for schizophrenia.

S Leucht1, J McGrath, W Kissling

  • 1Klinik für Psychiatrie und Psychotherapie, Klinikum rechts der Isar der TU-München, Ismaningerstr. 22, München, Germany.

The Cochrane Database of Systematic Reviews
|August 15, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Non-Response to Antidepressants: Risk Factors and Therapeutic Possibilities.

Pharmacopsychiatry·2026
Same author

Canadian Surgery Forum: Abstracts of presentations to the Annual Meetings of the Canadian Association of Bariatric Physicians and Surgeons, Canadian Association of General Surgeons, Canadian Association of Thoracic Surgeons, Canadian Hepato-Pancreato-Biliary Association, Canadian Society of Surgical Oncology, Canadian Society of Colon and Rectal Surgeons, Vancouver, BC, Sept. 17-21, 2013.

Canadian journal of surgery. Journal canadien de chirurgie·2025
Same author

Large-scale analysis of structural brain asymmetries during neurodevelopment: Associations with age and sex in 4265 children and adolescents.

Human brain mapping·2024
Same author

Sleep problems in children and adolescents in an attention deficit hyperactivity disorder service.

Irish journal of psychological medicine·2023
Same author

Risk factors for SARS-CoV-2 infection in healthcare workers following an identified nosocomial COVID-19 exposure during waves 1-3 of the pandemic in Ireland.

Epidemiology and infection·2022
Same author

Autism spectrum disorders: current issues and future directions.

Irish journal of psychological medicine·2022

Lithium monotherapy shows no benefit for schizophrenia treatment. While lithium augmentation may improve response rates, it leads to more participants leaving studies early, indicating inconclusive evidence for its effectiveness in schizophrenia management.

Area of Science:

  • Psychiatry and Mental Health
  • Pharmacology
  • Clinical Trials

Background:

  • Schizophrenia treatment often involves antipsychotic drugs, but many patients do not respond adequately.
  • Lithium is sometimes used as an add-on medication for treatment-resistant schizophrenia.

Purpose of the Study:

  • To systematically review the efficacy and safety of lithium in treating schizophrenia and schizophrenia-like psychoses.
  • To evaluate lithium as a standalone treatment versus antipsychotics and as an adjunct to antipsychotic therapy.

Main Methods:

  • Conducted a comprehensive search of the Cochrane Schizophrenia Group's register and other databases for randomized controlled trials (RCTs).
  • Included RCTs comparing lithium with antipsychotics, placebo, or no intervention, as monotherapy or augmentation.

Related Experiment Videos

  • Extracted and analyzed data independently, using relative risks and weighted mean differences.

    • Main Results:

    • Lithium monotherapy showed no significant difference compared to placebo.
    • Lithium as monotherapy against antipsychotics resulted in more early dropouts, suggesting lower efficacy.
    • Lithium augmentation showed a potential for clinically significant response but with borderline statistical significance and increased early discontinuations.

    Conclusions:

    • No randomized trial evidence supports lithium as a sole treatment for schizophrenia.
    • Evidence for lithium augmentation in schizophrenia is inconclusive, necessitating further large, well-designed trials.
    • Future research should focus on specific patient groups, including those without affective symptoms and those with schizoaffective disorders.